secwatch.observer — SEC 8-K summary
======================================

Issuer:     COLLEGIUM PHARMACEUTICAL, INC (COLL)
CIK:        0001267565
Form:       8-K/A
Filed at:   2026-06-30T20:05:46+00:00
Accession:  0001104659-26-079323
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Collegium closes $655.6M acquisition of AZSTARYS; Corium had going concern doubt
--------------------------------------------------------------------------------

- Acquired AZSTARYS (ADHD treatment) for ~$655.6M cash, funded by $355.6M cash on hand and $300M delayed draw term loan.
- Up to $135M in additional milestone payments if AZSTARYS achieves certain commercial and manufacturing targets.
- Corium's audited FY2025 net loss was $42.4M; accumulated deficit $736M; auditors flagged substantial doubt about going concern.
- Corium FY2025 product sales $113.6M, up from $79.6M in FY2024; operating loss improved to $14.7M from $127.2M.
- Pro forma financials filed; ADLARITY (Alzheimer's product) excluded as not part of acquisition.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1267565/000110465926079323/0001104659-26-079323-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1267565/000110465926079323/tm2618928d1_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-079323

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer